keyword
MENU ▼
Read by QxMD icon Read
search

Liver chemoembolization

keyword
https://www.readbyqxmd.com/read/28195873/niace-score-for-hepatocellular-carcinoma-patients-treated-by-surgery-or-transarterial-chemoembolization
#1
Xavier Adhoute, Guillaume Pénaranda, Jean Luc Raoul, Emilie Bollon, Bernard Pol, Yves P Letreut, Hervé Perrier, Olivier Bayle, Olivier Monnet, Patrick Beaurain, Cyril Muller, Jean Hardwigsen, Gaëlle Lefolgoc, Paul Castellani, Jean P Bronowicki, Marc Bourlière
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) prognostic scores could be useful in addition to the Barcelona Clinic Liver Cancer (BCLC) system to clarify patient prognosis and guide treatment decision. The NIACE (tumor Nodularity, Infiltrative nature of the tumor, serum Alpha-fetoprotein level, Child-Pugh stage, ECOG performance status) score distinguishes different prognosis groups among BCLC A, B, and C HCC patients. Our aims are to evaluate the NIACE score and its additive value in two HCC cohorts treated either by surgery or by chemoembolization, and then according to the BCLC recommendations...
February 13, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28193540/unusual-behaviour-induced-by-phase-separation-in-hydrogel-microspheres
#2
C L Heaysman, G J Phillips, A W Lloyd, A L Lewis
: Hydrogel microspheres with the capability to interact with charged species such as various drugs by ion-exchange processes are useful in a variety of biomedical applications. Such systems have been developed to allow active loading of the microsphere with chemotherapeutic agents in the hospital pharmacy for subsequent locoregional therapy of tumours in the liver by drug-eluting bead chemoembolization (DEB-TACE). A variety of microspherical embolisation systems have been described, all based upon hydrogels bearing anionic functionalities to allow interaction with cationically charged drugs...
February 10, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/28185998/study-on-the-effect-of-chemoembolization-combined-with-microwave-ablation-for-the-treatment-of-hepatocellular-carcinoma-in-rats
#3
Thomas Josef Vogl, Jun Qian, Andreas Tran, Elsie Oppermann, Nagy N Naguib, Huedayi Korkusuz, Nour Eldin A Nour Eldin, Wolf Otto Bechstein
PURPOSE: We aimed to evaluate the combining effects of transarterial chemoembolization (TACE) and open local thermal microwave ablation (MWA) in a hepatocellular carcinoma animal model. METHODS: Tumor cubes were implanted into the liver of 30 male inbred ACI rats. Groups of 10 animals were treated at 13 days (TACE or MWA) and 16 days (MWA) postimplantation with combined therapy (study group A) of TACE (0.1 mg mitomycin C; 0.1 mg iodized oil; 5.0 mg degradable starch microspheres) and MWA (2450 Mhz; 45 s; 35 W), TACE (control group B) or MWA (control group C) alone...
February 10, 2017: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/28185302/patterns-and-challenges-of-treatment-sequencing-in-patients-with-hepatocellular-carcinoma-experience-from-a-referral-center
#4
Martha M Kirstein, Nora Schweitzer, Theresa Winter, Katerina Lappas, Nathalie Graen, Isabell Kunstmann, Torsten Voigtländer, Tanja Reineke-Plaaß, Michael P Manns, Frank Lehner, Thomas Rodt, Arndt Vogel
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers. Several local and systemic therapies are available for patients with HCC depending on the stage of the disease. In clinical practice, treatment decision-making and sequencing may be very heterogeneous. METHODS: In this study, we retrospectively analyzed treatment algorithms in 2,101 patients with HCC treated from 2000 to 2015 at Hannover Medical School, Germany. RESULTS: Transarterial chemoembolization (TACE) was the most common initial treatment (n = 545; 25...
February 10, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28181172/discrepant-imaging-findings-of-portal-vein-thrombosis-with-dynamic-computed-tomography-and-computed-tomography-during-arterial-portography-in-hepatocellular-carcinoma-possible-cause-leading-to-inappropriate-treatment-selection
#5
Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Kazuyuki Mizuno, Natsuko Kobayashi, Yosuke Inukai, Akira Takeda, Yasuhiro Sone
We encountered a patient with hepatocellular carcinoma who had discrepant imaging findings on portal vein thrombosis with portal phase dynamic computed tomography (CT) and CT during arterial portography (CTAP). CTAP, via the superior mesenteric artery and via the splenic artery, both showed a portal perfusion defect in the right hepatic lobe, indicating portal vein thrombosis in the main trunk of the right portal vein. Portal phase dynamic CT clearly depicted portal perfusion of the same hepatic area. Transarterial chemoembolization was successfully performed, but it was associated with severe liver injury...
February 8, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28170405/treatment-algorithm-based-on-the-multivariate-survival-analyses-in-patients-with-advanced-hepatocellular-carcinoma-treated-with-trans-arterial-chemoembolization
#6
Hasmukh J Prajapati, Hyun S Kim
PURPOSE: To develop the treatment algorithm from multivariate survival analyses (MVA) in patients with Barcelona clinic liver cancer (BCLC) C (advanced) Hepatocellular carcinoma (HCC) patients treated with Trans-arterial Chemoembolization (TACE). METHODS: Consecutive unresectable and non-tranplantable patients with advanced HCC, who received DEB TACE were studied. A total of 238 patients (mean age, 62.4yrs) was included in the study. Survivals were analyzed according to different parameters from the time of the 1st DEB TACE...
2017: PloS One
https://www.readbyqxmd.com/read/28166821/deb-tace-for-intermediate-and-advanced-hcc-initial-experience-in-a-brazilian-cancer-center
#7
Jose Hugo Mendes Luz, Paula M Luz, Henrique S Martin, Hugo R Gouveia, Raphal Braz Levigard, Felipe Diniz Nogueira, Bernardo Caetano Rodrigues, Tiago Nepomuceno de Miranda, Marcelo Henrique Mamede
BACKGROUND: According to Barcelona Clinic Liver Cancer classification transarterial chemoembolization is indicated in patients with Hepatocellular Carcinoma in the intermediate stage. Drug-eluting microspheres can absorb and release the chemotherapeutic agent slowly for 14 days after its intra-arterial administration. This type of transarterial chemoembolization approach appears to provide at least equivalent effectiveness with less toxicity. METHODS: This is a prospective, single-center study, which evaluated 21 patients with intermediate and advanced hepatocellular carcinoma who underwent transarterial chemoembolization with drug-eluting microspheres...
February 6, 2017: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/28160267/third-line-treatment-of-colorectal-liver-metastases-using-debiri-chemoembolization
#8
Germano Scevola, Giorgio Loreni, Marco Rastelli, Stefano Sposato, Sara Ramponi, Vittorio Miele
To evaluate safety, efficacy of drug-eluting beads with irinotecan (DEBIRI) on local response and survival of patients affected by colorectal liver metastases (CRLM) progressing during or after second line was evaluated. Sixty-two patients, with colorectal liver metastases, not suitable for surgery or thermal ablation treatments, progressing during or within 6 month from the end of second-line chemotherapy, were treated with DEBIRI chemoembolization between February 2009 and July 2014. CRLM were histologically confirmed...
March 2017: Medical Oncology
https://www.readbyqxmd.com/read/28160206/distribution-of-tumor-stage-and-initial-treatment-modality-in-patients-with-primary-hepatocellular-carcinoma
#9
X Xiang, J-H Zhong, Y-Y Wang, X-M You, L Ma, B-D Xiang, L-Q Li
OBJECTIVE: This study reviewed the distribution of each tumor stage and each type of initial treatment modality among patients with primary hepatocellular carcinoma (HCC) treated at a tertiary tumor hospital between January 2003 and October 2013. METHODS: Baseline data of patients with primary hepatocellular carcinoma treated between January 2003 and October 2013 were retrospectively collected. Tumor stage was determined according to the Barcelona Clinic Liver Cancer (BCLC) staging system and Hong Kong Clinic Liver Cancer (HKLC) staging system...
February 3, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28157070/overall-survival-in-response-to-sorafenib-with%C3%A2-transarterial-chemoembolization-for-bclc%C3%A2-stage-b-hepatocellular-carcinoma-propensity%C3%A2-score-analysis%C3%A2
#10
Yonghui Huang, Bin Chen, Ni Liu, Nan Li, Haitao Dao, Wei Chen, Jianyong Yang
OBJECTIVE: Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC) is a heterogeneous disease group. Transarterial chemoembolization (TACE) is indicated for BCLC stage B HCC, while sorafenib is indicated for BCLC stage C HCC. This study aimed to evaluate the efficacy of TACE+sorafenib compared with TACE monotherapy in the treatment of BCLC stage B HCC. MATERIALS: Patients with BCLC stage B unresectable HCC. METHODS: This was a retrospective study in patients with BCLC stage B HCC who received TACE (n = 144) or TACE+sorafenib (n = 46) between January 2008 and January 2014...
February 3, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28155861/preoperative-adjuvant-transarterial-chemoembolization-cannot-improve-the-long-term-outcome-of-radical-therapies-for-hepatocellular-carcinoma
#11
Lei Jianyong, Zhong Jinjing, Yan Lunan, Zhu Jingqiang, Wang Wentao, Zeng Yong, Li Bo, Wen Tianfu, Yang Jiaying
Combinations of transarterial chemoembolization (TACE) and radical therapies (pretransplantation, resection and radiofrequency ablation) for hepatocellular carcinoma (HCC) have been reported as controversial issues in recent years. A consecutive sample of 1560 patients with Barcelona Clinic Liver Cancer (BCLC) stage A/B HCC who underwent solitary Radiofrequency ablation (RFA), resection or liver transplantation (LT) or adjuvant pre-operative TACE were included. The 1-, 3- and 5-year overall survival rates and tumor-free survival rates were comparable between the solitary radical therapy group and TACE combined group in the whole group and in each of the subgroups (RFA, resection and LT) (P > 0...
February 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28154910/value-of-tumor-stiffness-measured-with-mr-elastography-for-assessment-of-response-of-hepatocellular-carcinoma-to-locoregional-therapy
#12
Sonja Gordic, Jad Bou Ayache, Paul Kennedy, Cecilia Besa, Mathilde Wagner, Octavia Bane, Richard L Ehman, Edward Kim, Bachir Taouli
PURPOSE: The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA). MATERIAL AND METHODS: This retrospective study was IRB-approved and the requirement for informed consent was waived...
February 2, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28154776/portal-vein-tumor-thrombus-is-a-bottleneck-in-the-treatment-of-hepatocellular-carcinoma
#13
Ju-Xian Sun, Jie Shi, Nan Li, Wei-Xing Guo, Meng-Chao Wu, Wan-Yee Lau, Shu-Qun Cheng
The effect of portal vein tumor thrombus (PVTT) on the prognosis of patients with hepatocellular carcinoma has become clear over the past several decades. However, identifying the mechanisms and performing the diagnosis and treatment of PVTT remain challenging. Therefore, this study aimed to summarize the progress in these areas. A computerized literature search in Medline and EMBASE was performed with the following combinations of search terms: "hepatocellular carcinoma" AND "portal vein tumor thrombus." Although several signal transduction or molecular pathways related to PVTT have been identified, the exact mechanisms of PVTT are still largely unknown...
December 2016: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/28152680/recommendations-for-the-delivery-of-focal-tumor-ablation-services
#14
Cassandra McKay, Jonathan Wang, Fulvia Baldassarre, Amanda Wong, Deanna Langer, John Kachura, Julian Dobranowski
: 106 Background: The objective of this work was to develop recommendations for the organization and delivery of focal tumor ablation services. New, minimally-invasive ablation technologies such as radiofrequency ablation (RFA), microwave ablation (MWA), and transcatheter arterial chemoembolization (TACE) offer treatment options for patients with a variety of cancers. These emerging therapies can improve patient care (minimize side-effects, offer more rapid recovery with comparable or enhanced outcomes) compared to traditional approaches...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28144882/efficacy-and-toxicity-of-transarterial-chemoembolization-therapy-using-cisplatin-and-gelatin-sponge-in-patients-with-liver-metastases-from-uveal-melanoma-in-an-asian-population
#15
Yoshitsugu Shibayama, Kenjiro Namikawa, Miyuki Sone, Akira Takahashi, Arata Tsutsumida, Shunsuke Sugawara, Yasuaki Arai, Yukiko Aihara, Shigenobu Suzuki, Juichiro Nakayama, Shinichi Imafuku, Naoya Yamazaki
BACKGROUND: Although both immune-checkpoint inhibitors and targeted therapies such as MEK inhibitors have been evaluated in metastatic uveal melanoma, the efficacy of these therapies is modest to date. The purpose of this study was to evaluate the efficacy and toxicity of transarterial chemoembolization (TACE) therapy for liver metastasis from uveal melanoma in an Asian population. METHODS: We retrospectively assessed the clinical data of patients with liver metastases from uveal melanoma who received TACE therapy using cisplatin (70 mg/m(2)) and gelatin sponge between 1997 and 2008...
January 31, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28144812/clinical-validity-of-metroticket-calculator-in-transplant-patients-undergoing-prior-chemoembolization-for-hepatocellular-carcinoma
#16
Hyung-Don Kim, Gi-Won Song, Ju Hyun Shim, Seungbong Han, Jihyun An, Deok-Bog Moon, Kang Mo Kim, Young-Suk Lim, Gi-Young Ko, Shin Hwang, Han Chu Lee, Eunsil Yu, Kyu-Bo Sung, Sung-Gyu Lee
AIM: To test the predictive performance of the Metroticket calculator for survival after liver transplantation (LT) of patients with hepatocellular carcinoma (HCC) undergoing prior transarterial chemoembolization (TACE). METHODS: A total of 142 patients treated with TACE and subsequent LT who had arterial enhancing HCC(s) were entered into this analysis. Tumor parameters measured by the enhancement radiological method pre-LT or by pathology post-LT were incorporated into the Metroticket analysis...
January 31, 2017: Hepatology International
https://www.readbyqxmd.com/read/28144610/pediatric-hepatocellular-carcinoma-challenges-and-solutions
#17
REVIEW
Irene Schmid, Dietrich von Schweinitz
Hepatocellular carcinoma (HCC) is a very rare entity in children, making it nearly impossible to orchestrate Phase II/III studies even as multinational cooperative trials. In contrast to adults, nearly 50% of the children have a response (α-fetoprotein decline and/or tumor shrinkage) to chemotherapeutic agents such as cisplatin and doxorubicin (PLADO), demonstrating that HCC in childhood can be chemotherapy sensitive. As a result, the main treatment options in pediatric HCC focus on systemic drug therapies and resection as the central therapy...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/28133345/-introduction-of-hyperthermia-therapy-with-low-dose-systemic-chemotherapy-and-hepatic-transarterial-chemo-embolization-for-a-case-of-advanced-prostatic-cancer
#18
Atsushi Hori, Takeo Yuki, Keita Yamashiro, Ryosuke Ohira, Shinichi Hori
The case of a 78-year-old man with hormone-independent locally advanced prostatic cancer with liver metastases is reported. Standard systemic chemotherapy was not administered due to his poor general condition. At the initial consultation, rapidly growing liver metastases, multiple lymph node metastases, and extensive locally advanced prostatic lesions were found. Transcatheter arterial chemoembolization, low dose systemic chemotherapy, and thermotherapy were administered. After introduction of this combination therapy, marked regression of all of the lesions, including the liver metastases, lymph node metastases, and pelvic extension was observed...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133140/-multiple-metachronal-liver-metastases-from-a-rectal-neuroendocrine-tumor-controlled-by-repeated-transcatheter-arterial-chemoembolization
#19
Yoshihiro Morimoto, Yoshinori Kagawa, Atsushi Naito, Takeshi Kato, Yasuo Oneda, Tomo Ishida, Yasufumi Sato, Ryuichi Kuwahara, Kohei Murakami, Yoshiteru Katsura, Yoshiaki Ohmura, Atsushi Takeno, Yutaka Takeda, Shigeyuki Tamura
A 60-year-old woman was diagnosed with a rectal neuroendocrine tumor(NET)with SM invasion.We performed laparoscopic low anterior resection with D3 lymph node dissection.Pathological findings were rectal NET, G1, pSM(9,000 mm), ly0, v0, pN0, PM0, DM0, pR0, pStage I .Four years and 6 months later, contrast enhanced abdominal computed tomography (CECT)and contrast enhanced magnetic resonance imaging revealed multiple liver metastases.The tumors were unresectable because they were bilobar; therefore, we performed transcatheter arterial chemoembolizaion(TACE)...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133133/-a-rare-complication-of-transcatheter-arterial-injection-for-multiple-liver-metastases-of-rectal-neuroendocrine-tumor-a-case-report
#20
Kensuke Suzuki, Nozomu Sakai, Hiroaki Shimizu, Masayuki Ohtsuka, Hideyuki Yoshitomi, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Shigetsugu Takano, Daisuke Suzuki, Shingo Kagawa, Hiroyuki Nojima, Masaru Miyazaki
A 50-year-old man was diagnosed with multiple bilobar liver metastases of rectal neuroendocrine tumor(NET). Although he received octreotide for 6 months and everolimus for 10 months, the liver metastases gradually increased in size. Therefore, we decided to perform transcatheter arterial infusion(TAI)with miriplatin. The serum total bilirubin level increased to 13.1 mg/dL 9 days after treatment, and it took 2 months to return to the normal range. CT scan demonstrated that most of the liver tumors had remarkably shrunk 4 months after treatment, and the patient has no sign of tumor regrowth even 12 months after treatment...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
72036
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"